Area of research
Hematology · Molecular Biology
Research interest
Research interests include Multiple Myeloma Research and Treatments, Protein Degradation and Inhibitors, Peptidase Inhibition and Analysis, and Histone Deacetylase Inhibitors Research.
High-dose melphalan treatment significantly increases mutational burden at relapse in multiple myeloma
ETV4-Dependent Transcriptional Plasticity Maintains <i>MYC</i> Expression and Results in IMiD Resistance in Multiple Myeloma
Prognostic impact of <i>NPM1</i> and <i>FLT3</i> mutations in patients with AML in first remission treated with oral azacitidine
Multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple myeloma
Multiple Myeloma DREAM Challenge reveals epigenetic regulator PHF19 as marker of aggressive disease
High-Dose Melphalan Significantly Increases Mutational Burden in Multiple Myeloma Cells at Relapse: Results from a Randomized Study in Multiple Myeloma
Translational and Clinical Evidence of a Differentiated Profile for the Novel CELMoD, Iberdomide (CC-220)
Multiple Myeloma DREAM Challenge Reveals Epigenetic Regulator <i>PHF19</i> As Marker of Aggressive Disease
Crowdsourced High-Risk Classifiers for Multiple Myeloma Patients Commonly Identify PHF19 As a Robust Progression Biomarker
Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma
A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis
Activity of lenalidomide in mantle cell lymphoma can be explained by <scp>NK</scp> cell‐mediated cytotoxicity
Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma
Safety and Efficacy of AG-221, a Potent Inhibitor of Mutant IDH2 That Promotes Differentiation of Myeloid Cells in Patients with Advanced Hematologic Malignancies: Results of a Phase 1/2 Trial
Absence of mutations in cereblon (CRBN) and DNA damage-binding protein 1 (DDB1) genes and significance for IMiD therapy